GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » ROE %

Genelux (Genelux) ROE % : -181.73% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Genelux ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Genelux's annualized net income for the quarter that ended in Mar. 2024 was $-31.40 Mil. Genelux's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $17.28 Mil. Therefore, Genelux's annualized ROE % for the quarter that ended in Mar. 2024 was -181.73%.

The historical rank and industry rank for Genelux's ROE % or its related term are showing as below:

GNLX' s ROE % Range Over the Past 10 Years
Min: -433.14   Med: 0   Max: 0
Current: -433.14

GNLX's ROE % is ranked worse than
95.22% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs GNLX: -433.14

Genelux ROE % Historical Data

The historical data trend for Genelux's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux ROE % Chart

Genelux Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
- - - -

Genelux Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -186.67 -92.39 -124.45 -181.73

Competitive Comparison of Genelux's ROE %

For the Biotechnology subindustry, Genelux's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genelux's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelux's ROE % distribution charts can be found below:

* The bar in red indicates where Genelux's ROE % falls into.



Genelux ROE % Calculation

Genelux's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-28.297/( (-35.783+19.473)/ 2 )
=-28.297/-8.155
=N/A %

Genelux's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-31.4/( (19.473+15.084)/ 2 )
=-31.4/17.2785
=-181.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Genelux  (NAS:GNLX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-31.4/17.2785
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-31.4 / 0.032)*(0.032 / 26.2845)*(26.2845 / 17.2785)
=Net Margin %*Asset Turnover*Equity Multiplier
=-98125 %*0.0012*1.5212
=ROA %*Equity Multiplier
=-117.75 %*1.5212
=-181.73 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-31.4/17.2785
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-31.4 / -31.4) * (-31.4 / -32.46) * (-32.46 / 0.032) * (0.032 / 26.2845) * (26.2845 / 17.2785)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9673 * -101437.5 % * 0.0012 * 1.5212
=-181.73 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Genelux ROE % Related Terms

Thank you for viewing the detailed overview of Genelux's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genelux (Genelux) Business Description

Traded in Other Exchanges
N/A
Address
2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Executives
Tony Yu officer: VP, Clinical Trial Operations C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay 10 percent owner C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder officer: General Counsel C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick director, officer: President and CEO C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello officer: VP, Pharmaceutical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett officer: Head of Quality C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling officer: Head of Regulatory C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang officer: Associate VP, Research C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla officer: Chief Medical Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361